NA-931

Intervention Phase 2

6 papers7 findings

2 independent labs
3 trials, none about aging, 2 with no results posted

Human trial5

Outcomes

Body weight

downin humans5−6.4%

5 studies

NA-931 decreases body weight in humans (5.1% greater reduction compared to placebo, p < 0.001).
“Participants receiving 150 mg/day lost up to 6.8% of body weight, representing a 5.1% greater reduction compared to placebo (p < 0.001).”
Human trialobesityoral150 mg/day28 days
Neuro‐Metabolic Association in Alzheimer’s Disease and Obesity: Clinical Evaluation of NA‐831 and NA‐931
AAIC 2025 abstract23 Dec 2025
NA-931 decreases body weight in humans (up to 13.8 % at 150 mg daily dosage).
“NA-931 demonstrated dose-dependent reductions in mean body weight from baseline, up to 13.8 % at 150 mg daily dosage”
Human trial150 mg daily13-week
SAT-713 Phase 2 Clinical Trials Of Na-931 To Study Subjects Who Are Obese With At Least One Weight-related Comorbid Condition
ENDO 2025 abstract22 Oct 2025
NA-931 decreases body weight in humans (up to 6.4%).
“subjects receiving NA-931 (n=74) demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 6.4%.”
Human trial28 daysn = 74
NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss
ADA Scientific Sessions 2025 abstract13 Jun 2025
NA-931 decreases body weight in humans (up to 14.8% from baseline, 13.2% relative to placebo).
“up to 14.8 % at 150 mg daily dosage, or 13.2% % relative to placebo.”
Human trialobese or overweight150 mg daily13 weeks
Associations between Alzheimer's Disease (AD) and Obesity—Clinical Trials of NA-813 for AD and NA-931 for Obesity
ADA Scientific Sessions 2025 abstract13 Jun 2025
NA-931 decreases body weight in humans (up to 14.8% from baseline, 13.2% relative to placebo).
“up to 14.8 % at 150 mg daily dosage, or 13.2% % relative to placebo”
Human trialin adults who are obese or overweightup to 150 mg daily13-week
Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition
ADA Scientific Sessions 2025 abstract13 Jun 2025

Muscle mass

no changein humans1

1 study

NA-931 has no effect on muscle mass in humans.
“No muscle loss was observed.”
Human trialin overweight/obese participants28 days
NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss
ADA Scientific Sessions 2025 abstract13 Jun 2025

Muscle loss

no changein humans1

1 study

NA-931 has no effect on muscle loss in humans.
“No muscle loss was observed.”
Human trialin adults who are obese or overweight13-week
Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition
ADA Scientific Sessions 2025 abstract13 Jun 2025